Sunovion Signs Deal with Portuguese Company to Distribute Parkinson’s Drug
Sunovion Pharmaceuticals, a NEC member headquartered in Marlborough, MA, has signed a deal with Portuguese company Bial, granting it exclusive commercial license rights to Sunovion’s ‘Kynmobi’ Parkinson’s drug. The agreement allows Bial to handle the marketing applications and authorization procedures necessary for distribution and commercialization in Europe.
Sunovion will retain exclusive commercial rights to Kynmobi in North America and all other regions of the world excluding the European Union, the European Economic Area, and United Kingdom. An undisclosed amount in payment will be made to Sunovion for its supply of Kynmobi, and Bial hopes to submit a European marketing authorization application by the end of 2021. This deal comes at an important time, as more than 10 million people worldwide are predicted to be living with Parkinson’s disease by 2030.
According to Sunovion’s press release, “Kynmobi is the first and only sub-lingual (under the tongue) therapy available for the on-demand treatment of [Parkinson’s] episodes in the U.S. and Canada.”
The New England Council celebrates Sunovion Pharmaceuticals’ commitment to helping those suffering from Parkinson’s around the world.